Starpharma Holdings Limited
A$0.45+A$0.02 (+4.65%)
Starpharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
OTC · MRES · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Institute of Biomedical Research Corp.’s quoted price sits in the lower half of its reported 52-week range, 90.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.45+A$0.02 (+4.65%)
Starpharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
₪0.17-₪0.00 (-1.14%)
Bonus BioGroup Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
CA$0.08+CA$0.01 (+6.67%)
Resverlogix Corp.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
CHF 2.17-CHF 0.08 (-3.56%)
EvoNext Holdings S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.8% below the high.
$10.20+$0.10 (+0.99%)
Finch Therapeutics Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.65% below the high.
€0.21€0.00 (0.0%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
$0.12$0.00 (0.0%)
Hadasit Bio-Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 7.69% below the high.